BLAINTRAVENOUSSYRINGEPriority Review
Approved
Feb 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
25
Data completeness
4/8 — Partial
Priority Review
NEUPOGEN (filgrastim) by Amgen. Approved for leukocyte growth factor [epc]. First approved in 1991.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) cytokine indicated for chemotherapy-induced neutropenia and other leukocyte deficiencies. It works by stimulating the proliferation and differentiation of neutrophil precursor cells in the bone marrow. This foundational biologic has been a cornerstone of supportive cancer care since its 1991 approval.
$0.01BPart D
LOE ApproachingDeclining
As an originator product in LOE-approaching phase with $10M Part D spending, Neupogen faces significant biosimilar and generic competition; brand teams are likely consolidating or shifting focus to line extensions and retained-value strategies.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia
Started Jan 2026
100 enrolled
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Started Apr 2025
18 enrolled
Preeclampsia
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Started Mar 2025
18 enrolled
Preeclampsia
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Started Nov 2023
100 enrolled
Breast Neoplasms
Worked on NEUPOGEN at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.